|Bid||7,891.00 x 0|
|Ask||7,894.00 x 0|
|Day's range||7,692.00 - 7,948.00|
|52-week range||109.51 - 72,750.00|
|Beta (5Y monthly)||0.20|
|PE ratio (TTM)||49.42|
|Earnings date||14 Feb 2020|
|Forward dividend & yield||2.19 (2.84%)|
|Ex-dividend date||08 Aug 2019|
|1y target est||78.83|
These two stocks offer growth today and protection in case of a market correction, in my opinion.The post No savings at 40? I’d buy these 2 fast-growing FTSE 100 stocks to top up the State Pension appeared first on The Motley Fool UK.
(Bloomberg) -- Want the lowdown on European markets? In your inbox before the open, every day. Sign up here.AstraZeneca Plc will stop testing a fish-oil pill for a form of harmful cholesterol that was in the most advanced and expensive stage of clinical trials.The medicine, called Epanova, didn’t stand a very high likelihood of showing a benefit when combined with a statin for patients at risk of heart disease due to high levels of LDL (or bad) cholesterol, Astra said in a statement Monday.Epanova, gained in Astra’s 2013 takeover of Omthera Pharmaceuticals, is a prescription omega-3 capsule approved to treat high levels of triglycerides, which also clog up patients’ arteries. Fish oils contain fatty acids that help combat deposits in blood vessels.“Epanova would have rounded out Astra’s growing suite of differentiated cardiovascular disease assets,” Andrew Baum, an analyst at Citi, wrote in a note to clients. He cited medicines such as Brilinta for heart disease, Farxiga, a diabetes drug that’s also approved for heart failure, and roxadustat, an anemia treatment.A write-down of as much as $100 million related to inventories will impact core earnings in the fourth quarter of 2019, Astra said. The company will review the drug’s $533 million value as an intangible asset. Astra shares were little changed in London.The failure is “a disappointment,” but isn’t having much impact on the stock because the drug’s estimated contribution to future sales was modest, according to Citi’s Baum. Analysts surveyed by Bloomberg expected the medicine to generate peak revenue of $145 million in 2023.(Updates with analyst’s comment in fourth paragraph)To contact the reporters on this story: Marthe Fourcade in Paris at email@example.com;Erin Roman in London at firstname.lastname@example.orgTo contact the editors responsible for this story: Eric Pfanner at email@example.com, John LauermanFor more articles like this, please visit us at bloomberg.com©2020 Bloomberg L.P.
The biggest British drugmaker by market value said the decision, which followed recommendations from an independent data monitoring committee, was due to low likelihood of Epanova's benefit to patients with mixed dyslipidaemia. "We are disappointed by these results, but we remain committed to addressing the needs of patients in the cardiovascular space where we have an extensive pipeline," Mene Pangalos, the executive vice president of biopharmaceuticals research and development, said. AstraZeneca added Epanova, which is is already approved in the United States to reduce high levels of triglyceride, to its pipeline when it bought U.S.-based Omthera Pharmaceuticals in 2013 to build up its cardiovascular drug business.
Stockopedia’s own data points to a jarringly simple stock market truth amidst the daily whirlwind of financial data: share prices that have gone up tend to kee8230;
These two FTSE 100 (INDEXFTSE:UKX) shares could offer higher income returns than a Cash ISA in my opinion.
AstraZeneca today announced the US Food and Drug Administration (FDA) has accepted a supplemental New Drug Application (sNDA) and granted Priority Review for FARXIGA® (dapagliflozin) to reduce the risk of cardiovascular (CV) death or the worsening of heart failure (HF) in adults with heart failure with reduced ejection fraction (HFrEF) with and without type 2 diabetes (T2D).
AstraZeneca and Merck & Co., Inc., Kenilworth, N.J., US (Merck: known as MSD outside the US and Canada) today announced that LYNPARZA® (olaparib) has been approved in the US for the maintenance treatment of adult patients with deleterious or suspected deleterious germline BRCA-mutated (gBRCAm) metastatic pancreatic adenocarcinoma whose disease has not progressed on at least 16 weeks of a first-line platinum-based chemotherapy regimen. Patients will be selected for therapy based on an FDA-approved companion diagnostic for LYNPARZA.
AstraZeneca and Merck's ovarian cancer drug Lynparza has received U.S. regulatory approval for the treatment of advanced pancreatic cancer, cementing its lead in a niche category of cancer treatments. The U.S. Food and Drug Administration (FDA) approved the drug's use as a first-line maintenance therapy for patients with BRCA gene mutations whose cancer had spread beyond the pancreas and whose tumours did not worsen after chemotherapy of at least 16 weeks, the British drugmaker said on Monday. Mutations in BRCA genes impair the ability to repair DNA damage and are typically linked with breast and ovarian cancers, but can occur in other cancers as well.
The AstraZeneca (LON:AZN) share price has risen by 7.64% over the past month and it’s currently trading at 7739p. For investors considering whether to buy, hol8230;
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today announced that the US Food and Drug Administration (FDA) has approved ENHERTU® (fam-trastuzumab deruxtecan-nxki) for the treatment of adult patients with unresectable or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting.
Investing.com -- Here is a summary of the most important regulatory news releases from the London Stock Exchange on Friday, 20th December. Please refresh for updates.
London's exporter-heavy FTSE 100 hit a more than four-month high on Thursday partly in response to a weaker pound, which came under pressure from fears Britain may leave the European Union without a trade deal at the end of 2020. The FTSE 100 was up by 0.4%, rising for the seventh straight session. Its gains have been supported by a breakthrough on a U.S.-China trade deal and a landslide victory for Prime Minister Boris Johnson in the British national election.
(Bloomberg Opinion) -- The U.K.’s election of a right-wing, pro-market government with a thumping majority would certainly seem like a green light to foreign companies wanting to buy London-listed rivals. But the new political climate for takeovers may be hazier than it seems.Boris Johnson’s administration is still only four months old, so it’s hard to know precisely how it would approach a sizable, serious, fully funded foreign takeover bid. The old chestnuts that surface now and again include an attempt on the big drugmakers, AstraZeneca Plc or GlaxoSmithKline Plc, a tilt by Exxon Mobil Corp. for BP Plc, or even a U.S. bid for BAE Systems Plc, despite the government having a veto via a “golden share.”A proposal to take over these particular British icons would be controversial, and each has its strategic and financial obstacles (AstraZeneca is expensive; oil companies are trying to get away from oil, not buy more). Yet getting the political calculation right may prove even trickier.Although Johnson hasn’t made the same protectionist noises as his predecessor, Theresa May, the U.K. has been taking a more interventionist stance on M&A lately. It’s now the norm for bidders in sensitive sectors to accept restrictions on how they’ll manage the assets they acquire, as seen most recently with the private-equity-led deals for defense contractor Cobham Plc and satellite operator Inmarsat Plc. The Competition and Markets Authority, the U.K.’s trustbuster, is getting tougher too. Witness its examination of Amazon.com Inc.’s minority stake in food-delivery group Deliveroo, even though the e-commerce giant would not have control.The question is whether the current level of scrutiny is where it peaks.Johnson is in a bind. The extra seats that delivered his majority were secured by votes potentially “lent,” to use the premier’s own phrase, from supporters of the opposition Labour Party, including those in Britain’s industrial heartlands. Johnson won’t want to alienate these voters by hastily endorsing deals that could threaten U.K. jobs or deliver prized national assets to foreign owners. Despite the Conservative Party’s longstanding laissez-faire approach to markets, the nationalist undercurrent remains strong in British politics.On the other hand, if the bearish analyses of Brexit's impact prove true, the U.K. economy is in for a difficult time in the years ahead. Johnson will want to attract foreign investment, and flat resistance to any overseas bid would surely be a deterrent to the international business audience. Potential U.S. bidders may judge that Johnson will also want to keep President Donald Trump happy if he is to secure the wide-ranging free-trade deal he campaigned on.Johnson, then, will be torn between his new Labour supporters and global business. Predicting where he’ll side isn’t easy. But when push comes to shove, and with the next election years away, it seems likely that he’d follow the money. Logic suggests that deal-hungry CEOs will now feel more confident testing Britain’s open-market credentials.To contact the author of this story: Chris Hughes at firstname.lastname@example.orgTo contact the editor responsible for this story: Timothy Lavin at email@example.comThis column does not necessarily reflect the opinion of the editorial board or Bloomberg LP and its owners.Chris Hughes is a Bloomberg Opinion columnist covering deals. He previously worked for Reuters Breakingviews, as well as the Financial Times and the Independent newspaper.For more articles like this, please visit us at bloomberg.com/opinion©2019 Bloomberg L.P.
A daily overview of the top business, market, and economic stories to watch in the UK, Europe, and abroad.
AstraZeneca and Daiichi Sankyo Company, Limited (Daiichi Sankyo) today presented positive detailed data from the global pivotal Phase II single-arm DESTINY-Breast01 trial of [fam]-trastuzumab deruxtecan (DS-8201), an investigational HER2-targeting antibody drug conjugate (ADC) and potential new medicine, in patients with HER2-positive metastatic breast cancer who received two or more prior HER2-targeted regimens.
An experimental cancer drug developed by AstraZeneca and Daiichi Sankyo kept metastatic breast cancer at bay for months in women who had exhausted other treatment options, its first clinical study showed. Patients on trastuzumab deruxtecan, also known as DS-8201, who had already undergone roughly six prior treatment courses, were saw no further progression for a median of 16.4 months. Jose Baselga, AstraZeneca's head of oncology research and development, said this patient group would normally encounter further cancer deterioration after about six months.
London's exporter-heavy FTSE 100 inched lower on Monday as oil majors and Asia-exposed financials fell on China growth worries and as the pound strengthened, while a 72% slump in Tullow Oil single-handedly dragged down midcaps. The blue-chip index was gave up 0.1%, with its dollar earners including spirits company Diageo and pharmaceutical giant AstraZeneca taking a hit from gains in sterling ahead of UK general election later this week. The FTSE 250 midcap index was also down by the same level, with Tullow Oil recording its steepest one-day fall since early 2004 after the oil and gas explorer scrapped dividend and announced the exit of its CEO.